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As perinatally infected adolescents living with HIV (ADLHIV) grow older and gain a greater 
sense of independence, disclosure issues and adherence to antiretroviral treatment (ART) 
have become major concerns. However, research on how adolescents view and cope with 
these challenges remains limited, especially in Sub-Saharan Africa.  We explored ADLHIV’s 
understanding of their infection and its perceived effects on their wellbeing, and ultimately, 
on their attitude towards life-long adherence to ART. 
 
Methods  
To this end,  a literature review was undertaken, to explore existing literature on experiences 
of adolescents living with HIV (ADLHIV), on antiretroviral treatment (ART). The review 
included both qualitative and quantitative studies, since 2000, with particular attention given 
to research conducted in the context of sub-Saharan Africa.  Studies reporting on 
psychosocial factors and how these impact on adherence were sought. To this end, 4 major 
themes viz: knowledge, experience, disclosure and adherence served as the search engine 
drivers. A total of 24 perinatally infected male and female ADLHIV, aged 10-15 years, 
attending an adolescent ART clinic in South Africa, were included in this exploratory study. 
12 in-depth qualitative interviews and 2 focus group discussions, were conducted.  
Qualitative data were analyzed using grounded theory. Ethical approval for the study was 
granted by the University of Cape Town Health Sciences Faculty Human Research and 
Ethics Committee. In addition, consent to conduct the research was granted by the Western 
Cape Provincial Department of Health, and the Gugulethu Community Health Centre/Hannan 
Crusaid antiretroviral clinic. Written consent to participate, and for the use of an audio-
recorder, during the interviews, was obtained from the legal guardians of each of the study 
participants, in addition, assent was obtained from all the study participants.  
 
Results 
Most of the adolescents demonstrated good knowledge and understanding around HIV, how 
it affects their health and the n ed for life-long ART. There was general acceptance, but also 
occasional resentment, anger and frustration regarding HIV and the need for life-long 
treatment.  Nonetheless, their experiences were mostly positive, despite the negative effects 
of stigma and community attitudes.  Knowing that there are others like them, also had a 
significant impact on how they experienced HIV. Many expressed appreciation for the effects 




Despite the challenges of living with HIV, adherence being the major one, most of the young 
adolescents have good insights regarding the need for life-long ART and genuine motivation 
to remain adherent.  
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Part A: Protocol 
 
Introduction and Background  
 
The prevalence of HIV among children under the age of 15 in South Africa was estimated at 
2.5% in 2008, mostly from perinatal transmission (Grey, 2009). The introduction and 
subsequent roll-out of antiretroviral treatment (ART) has led to a dramatic improvement in 
the survival rate of HIV+ children in this country.  With the largest ART programme in the 
world to date, approximately 32 000 children under 15 years were noted to be on treatment in 
2007 (Davies et al, 2009).  Furthermore, a study looking at treatment outcomes of HIV 
positive children who access ART under the age of 16 showed a 7.7% mortality and 81.1% 
retention in care 3 years following ART initiation (Davies et al, 2009).   
 
Thus, due to ART, an increasing number of children in Sub-Saharan Africa are surviving and 
reaching adolescence. However, a study by Nachega et al. (2009) showed that ART 
adherence among adolescents was significantly lower than that of adults, which led to poorer 
virologic and immunologic outcomes.  In this study, it was shown that “adolescents were 
approximately 50% less likely than adults to maintain perfect adherence at all time points” 
(Nachega et al, 2009, p. 68).  In view of these findings, a new frontier of challenges, where 
this epidemic is concerned, has now been reached regarding this particular population.  
Disclosure issues, adherence to ART and transmission of resistant HIV have become major 
concerns.  The latter two issues especially, could potentially pose a serious public health 
challenge in the near future (Wiener et al, 2007).   
 
Furthermore, adolescents in general, pose a real challenge to health care givers in terms of 
knowing and having their needs met adequately.  Poor health seeking behaviour due to fear, 
denial or cultural perspectives, inability to communicate and/or express themselves or their 
needs clearly, and a general wariness of adults, are some of the contributing factors 
(Augustine, 2002). In addition, adolescents are generally perceived by adults as a difficult 
group of patients because of the complexity of their status as adolescents, going through the 
challenges of adolescence.  The consequence has therefore been that insights pertaining to 
their needs when it comes to health care services have remained fairly limited.  In addition, 
historically, adolescent health has been a fairly neglected area of medicine, which has 
resulted in a severe lack of skilled health care givers with specialised training in the 
management of adolescent health.   
 
Adolescents with chronic diseases such as HIV are expected to assume greater and greater 
responsibility for their disease management as they grow older and gain a greater sense of 
independence.  In addition, they have to make decisions about disclosure to peers and sexual 
partners, and risk the possibility of rejection and/or stigmatisation from peers.  These 
challenges tend to impact negatively on their adherence (Marhefka et al, 2008; Wiener et al, 
2007).  For this emerging population, how they view and cope with these challenges in the 
worlds that they live in necessitates further studies (Wiener et al, 2007).   
 
There is paucity in research data on how young adolescents living with HIV experience HIV 
and ART; what their knowledge, understanding and views are; how socio-cultural influences 
impact on these experiences and subsequently on adherence; and finally, how they see the 















infected adolescents living with HIV (ADLHIV), remains fairly neglected in sub-Saharan 
Africa.  The focus, so far, has been on adherence in association with virologic outcomes, or 
care-giver characteristics and influences. Perhaps it’s the fact that their age and therefore 
vulnerability as potential research participants poses serious ethical challenges.  That, and 
also the need for special techniques and provisions upon their inclusion in research, has 
added to the reluctance of recruiting them as study participants.  However, in order to stem 
the tide of poor adherence and sexual transmission of multi-drug resistant HIV once these 
adolescents become sexually active, there is a need to address the above issues while they are 
pre-pubescent and prior to their sexual debut, because failing to do so has serious public 
health implications; thus the study.  
 
Problem Statement 
Studies done on ADLHIV found factors such as forgetfulness, busy schedules, interruption of 
daily routine and stigma being cited as reasons for poor adherence (Nachega et al, 2009).  
Given the increase in survival of ADLHIV on ART, it is becoming increasingly important to 
identify barriers to adherence in this population in order to design appropriate and effective 
interventions.  However, research in this area thus far has been fairly limited, especially in 
Sub-Saharan Africa (Nachega et al, 2009).  In particular, research regarding adolescent HIV 
has been conducted mostly among adolescents in developed countries, mostly the USA.  The 
majority of those studies have focused on older adolescents (>15yrs) with horizontally 
(behaviourally) acquired HIV.  In addition, the focus, in this population, has been largely on 
adherence in relation to virologic suppression rates/outcomes, which is a real challenge with 
regard to adolescent care in HIV management (Williams et al, 2010).  And finally, the 
research methods have mostly been quantitative (Grey, 2009). 
 
There is thus a need to look at younger ADLHIV (<16yrs), in a developing country e.g. South 
Africa. Focusing specifically on adolescents with a history of vertical transmission, gaining 
insights into their experience of HIV and ART, i.e. attitudes and perceptions, and how these 
affect their adherence to ART, will be particularly valuable in understanding barriers and 
facilitators to adherence.  In addition, given the gendered nature of the HIV epidemic in sub-
Saharan Africa, examining gender issues and cultural influences among perinatally infected 
adolescents and how these factors impact on their experience of HIV in their communities 
and ultimately their adherence to ART, is pertinent.  
 
Study Aims 
The primary aim of this study is to attempt to see HIV through the eyes of a young, 
perinatally infected, asymptomatic ADLHIV, by exploring what their understanding of their 
illness is and its perceived effects on their health, body and self-image, in order to develop 
novel and effective ways of meeting their healthcare needs.   
Secondly, to examine how socio-cultural factors such as gender, cultural influences and 
community issues, impact on the adolescents’ experience of HIV in the communities they 
find themselves in. Hopefully, developing such insights can aid in more appropriate 
messaging regarding HIV and the importance of adherence for young ADLHIV on ART. 
 
Research Questions (These will form the basis of the qualitative interview questions) 
1. How does the young, asymptomatic ADLHIV perceive HIV and the importance of 
adherence to ART? 
 Sub-questions: 
 What are the attitudes, knowledge and experiences among young perinatally 















 What are their opinions and understanding of the need to continue taking 
medication in order to stay well, i.e. adherence to ART? 
  
2. What are the key factors that affect ADLHIV’s perceptions with regard to their HIV 
status?  
 Sub-question: 
How do socio-cultural factors such as, gender, cultural influences and community 
attitudes impact on the ADLHIV’s experience of HIV and ultimately on their 
adherence to ART? 





2.0 Study Methodology 
 
2.1 Study design 
 
This is a qualitative study using in-depth interviews and focus group discussions.  Drawings 
will be used as probes during in-depth interviews, to aid in drawing out information from the 
study participants, especially the 10 - 12 year olds.   
 
2.2 Study population 
The study population will come from the Hannan Crusaid adolescent ARV clinic, which is 
part of the Gugulethu Community Health Centre.  Gugulethu is a peri-urban settlement in the 
Klipfontein sub-district of Cape Town, with a combination of formal and informal houses. 
Out of a total population of   ~ 350 000, the unemployment rate is approximately 57%, and 
about 81% of the population lives in informal housing (Bekker et al, 2006).  
 
The Hannan Crusaid adolescent ARV clinic was launched in 2008, and primarily provides 
ART to ADLHIV from the Gugulethu area between the ages of 10 and 19 years, as per WHO 
definition. This service is provided in an adolescent friendly environment that takes into 
account adolescents’ challenging developmental needs in accordance with the Youth Friendly 
Services initiative by Lovelife (Augustine, 2002).  Given that the PMTCT programme 
coverage in developing countries was only 45% in 2008, (Richter et al, 2010), the majority of 
the adolescents attending this  clinic also have a history of vertical transmission of HIV, and 
many of  them  were diagnosed and  had their treatment initiated at Red Cross children's 
hospital.  They are initially transferred into the main Hannan Crusaid ARV clinic, which has 
been providing adult and paediatric ART services to the Gugulethu community since 2002.  
They are then transferred into the above clinic soon after their 10
th
 birthday, and full 
disclosure is a pre-condition, prior to the transfer. Doctors, nurses and counselors dedicated to 
the adolescent clinic facilitate the delivery of care.   
 
The Hannan Crusaid adolescent ARV clinic is chosen because of several unique aspects, viz: 
this adolescent clinic functions primarily as a referral facility, therefore all the adolescents 
seen at this facility are HIV+ and on ART or are being worked up to start ART.  It does not 
provide additional services such as VCT testing, Family Planning or TOP services.  This is 
what distinguishes this clinic from other youth clinics e.g. in the Khayelitsha sub-district, 
















This population is chosen because: (a) they have all been on ART since early childhood, (b) 
they have all been attending the Hannan Crusaid adolescent ARV clinic for more than 1year, 
and they all know their HIV status, (c) they are currently at various stages of development 
physically and psychologically, (d) they share similar backgrounds in terms of: geographic 
area, culture, schools, socio-economic circumstances and education levels of the care-givers, 
(e) adherence, now that they're a little older and no longer entirely dependant on their care-
givers, has become a major issue for many. 
 
The study population will consist of HIV+ adolescents on ART between the ages of 10 and 
15 yrs.  Study participants will need to meet the following inclusion criteria: (a) Infection 
through vertical transmission, (b) ART initiation prior to age 10, (c) Hannan Crusaid ARV 
clinic attendance since <10 years old, (d) they reside in the Gugulethu catchment area, (e) 
The study participant must have one principal legal guardian (Parent, Granny or Aunt/Uncle) 
who assists with medication and clinic attendance.  Recruitment will be done in a manner that 
is representative in terms of age and sex.   
 
  
2.3 Sampling and Recruitment 
Once consent to conduct the research and ethical approval for the study has been granted by 
the Western Cape Provincial Department of health and the UCT Health Sciences Faculty 
Human Research and Ethics Committee, respectively, recruitment of study participants will 
commence. 
 
Recruitment of participants into the study will be done via purposive sampling, common in 
qualitative research.  This manner of sampling will ensure that adolescents who are chosen 
meet the inclusion criteria as set out in the “Study Population” section above.  Due to the 
nature of the questions, purposive sampling will also ensure the inclusion of adolescents with 
some knowledge about HIV and the effects of ART.  In addition, purposive sampling will 
also ensure that they are a group who share a lot in common, such as: geographic area, 
schools, socio-economic circumstances, education levels of the care-givers and cultural 
background, to allow for meaningful comparisons.  
 
Due to the explorative nature of the research, and also because the study aims at taking an in-
depth  look at the subject at hand, a total of 12 in-depth interviews will be conducted.  The 
study participants will be categorised according to age and sex, and recruitment will be done 
in a manner that is representative in terms of these two categories. 
 
Two focus groups, consisting of a total of 12 participants, will be divided into two groups as 
follows: 10-12 yr. olds (6 participants), and 13-15 yr. olds, also consisting of 6 participants, 




3.0 Data Collection Methods 
This study will make use of qualitative tools and techniques of data collection. 
 
3.1 Study Duration 
The entire study will take approximately 6 Months from recruitment of study participants to 


















3.2 Data Collection Tools 
 
The data collection tools that will be utilized for this study will include in-depth interview 
guides and focus groups interview guides; and will utilise drawings, which will be used as 
probes during in-depth interviews. Studies have shown that art can be an effective tool when 
conducting interviews with children.  They have been found to be more effective 
communicators through art than verbally, and much can be revealed in terms of experiences, 
thoughts, hopes and how they make sense of confusing issues in their worlds (Kortesluoma et 
al, 2008).  
 
3.2.1 In-depth Interviews 
Qualitative in-depth, one-on-one interviews will be conducted with each participant.  Due to 
the sensitive nature of the topic, namely HIV, the privacy and individual attention provided 
by a one-on-one interview should enable the participants to talk more freely about their 
personal feelings and experiences. Disclosure issues, care-giver support issues and home 
environment enablers or challenges will also be best explored in this setting.  In addition, 
one-on-one interviews will create space for these young adolescents to express their 
individual perceptions and feelings regarding how they see the future; and their concerns 
regarding their future as HIVpositive individuals in society, free from peer pressure 
influences.  It will also provide insights into how they understand and/or what they make of 
all that is happening to them with regard to HIV and ART, and how it impacts on their daily 
lives.  
 
The main data collection technique that will be used will be in-depth, semi-structured, open-
ended interview guides. This technique will be used primarily to answer research question 1. 
As mentioned earlier, probes will be used during the interviews.  One means of probing will 
entail the use of drawings to aid the adolescents in demonstrating their understanding of the 
effects of HIV and ART in their bodies. Background socio-demographic information will be 
collected, such as: age, sex, grade in school, who the primary care-giver is, duration on ART 
and how long they have been attending the Hannan Crusaid adolescent clinic for. Instead of 
being collected prior to the interview, these will be used instead as “ice-breakers” at the start 
of the interview.  The interviews will be conducted at the Hannan Crusaid ARV clinic, in a 
counselling room, to ensure privacy.  These will be conducted on a Tuesday afternoon during 
the adolescents’ clinic visits, so as not to interfere with the study participants’ school time.   
 
Since the adolescents are primarily Xhosa-speaking, each interview will be conducted by a 
trained fieldworker in Isi-Xhosa, and will last approximately one hour. The researcher will 
play the role of overall facilitator, overseeing the entire data collection process, and ensuring 
the proper use of the digital recording device. However, in order to avoid the “white coat” 
effect, the researcher will not be present during the actual interviews.  Each recorded 
interview will be transcribed verbatim and then translated into English, for ease of analysis.  
Permission will be sought from the study participant and legal guardian for the use of an 
audio-recorder during the interviews. 
 
3.2.2 The two focus group interviews will also be conducted at the Hannan Crusaid ARV 
clinic, in a counselling room, to ensure privacy.  They will also be conducted on a Tuesday 
afternoon during the adolescent’s clinic visits, so as not to interfere with their school time.  















will be used primarily to answer research question 2.  The focus during these groups will be 
to share ideas regarding their health and experiences in their neighbourhoods, schools and 
communities; How they feel they may be perceived by peers and the community that they 
come from, cultural influences and how that affects their perceptions, understanding, feelings 
regarding their particular condition/status as HIV+ youth, stigma, etc.  The participants 
chosen for focus group interviews will be a totally different sample that will provide fresh, 
different and perhaps even completely unexpected perspectives on the issues around HIV and 
ART to be discussed.   
 
Similar to the one-on-one interviews, each focus group interview will be conducted by a 
trained fieldworker in Isi-Xhosa, and will last approximately one hour.  Once again, the 
researcher will play the role of overall facilitator, overseeing the entire data collection 
process, and ensuring the proper use of the digital recording device. As with the one-on-one 
interviews, the researcher will once again not be present during the actual interviews in order 
to avoid the “white coat” effect.  Similarly, the recorded interviews will be transcribed 
verbatim and then translated into English, for ease of analysis.  Each interview will last an 
hour. Permission will be sought from the study participant and legal guardian for the use of 
an audio-recorder during the interviews.  
 
 
3.3 Pilot Study 
 
A pilot study will be conducted to test the overall feasibility of the data collection methods 
and the study instruments.  Especially in view of the age and thus vulnerability of the study 
participants, checking the appropriateness, understanding, clarity and flow of the interview 
questions will be essential and revisions will be made where necessary. The pilot study will 
be conducted in the same facility by the researcher and a trained, Xhosa speaking, 
fieldworker.  A total of 5 adolescents varying in age from 10 – 15 years will be randomly 
chosen during clinic visiting time, for interviewing.  Those chosen will be the ones that are 
accompanied by a legal guardian, so as to obtain consent, prior to the interview. This process 
will be carried out over a two week period. The data gathered from the pilot study will not be 
included in the dissertation; in addition, the participants recruited for the pilot study will not 
be recruited for participation in the actual study. 
 
4.0 Data Management 
For confidentiality and security purposes, all data from this study (digital recordings of all 
interviews, transcripts and translated material) will be kept in a safe place (in a locked cub-
board). Copies of transcripts and translated material will be kept on 2 separate hard drives (1 
laptop and 1 external hard drive).  In addition, all material will be stored on 2 separate flash 
drives. Copies of the audio-tapes will also be made and kept in a safe place, different from 
where the original copies will be kept.  Nvivo data management package, which is one of 
many computer software packages used in qualitative analysis, will be used for this study, to 
facilitate data management and analysis.  
 
5.0 Data Analysis 
A grounded theory approach will be used to analyse the data.  Data will be explored in search 
of common themes and patterns. Because data analysis is an iterative process, each one-on-
one interview will be followed by a process that entails constant coding, reading, re-reading, 
rephrasing, analysing and verifying.  This same process will be applied following each focus 















analysis will begin in the field and will continue throughout the data collection period. The 
analysis will then extend beyond this period, identifying possible themes and developing 
tentative explanations.  There will be a constant search for core meanings of, opinions, 
thoughts, feelings and behaviour of the interviewees throughout the entire data collection and 
analysis process.  This will be followed by an overall interpretation of the study findings, to 
demonstrate how themes relate to one another and ultimately how concepts answer or 
respond to the original study questions.  Triangulation will be used to ensure rigor, by 
comparing findings with available data.    
 
6.0 Ethics 
Due to the age of the study participants, written, informed consent will have to be obtained 
from each of the participants’ legal guardians first, followed by individual assent from each 
participant. The written consent will be translated into and conducted in Isi-Xhosa for ease of 
understanding.  This will be done prior to the interviews. In addition, the parents/legal 
guardians will be assured that allowing their children to participate is purely voluntary and 
that they are free to withdraw their children from the study without fear of any penalties. In 
terms of assent, only those adolescents who give their assent will be recruited for the study. 
 
The recruitment of such young and thus vulnerable study participants raises quite a few 
ethical concerns.  (a) The parents/legal guardians may be concerned not only about their 
children being asked to speak to a stranger about sensitive issues such as their HIV status, 
social stigma, disclosure issues, loss suffered due to HIV/AIDS (commonly a parent), 
negative peer and community attitudes and perceptions, but also about the emotional and  
psychological effects of such discussions.  (b) They may also be concerned that they will not 
be present during the interview to protect their children if they become distressed.  (c) They 
may be concerned about the use of an audio-recorder, anonymity and confidentiality. 
 
In order to set the parents/legal guardians at ease, the study has built in measures to allay 
these fears, thus: (a) A youth counsellor that the study participants are used to interacting and 
engaging with at the clinic and who, in addition, has been receiving on-going training in 
distress management and youth counselling, will be present during the interview and will be 
facilitating the process.(b) Th y will be given an information leaflet detailing the study 
purpose, the interview process, the questions that will be asked and who to contact for further 
information upon recruitment and prior to the interviews.  (c) They will be assured of 
anonymity and confidentiality of all information shared during the interview in that the 
personal information shared will only be used as research data and will be managed in a 
manner that ensures anonymity and confidentiality. (d)They will also be assured that the 
interview process will be interrupted immediately if it causes undue emotional distress to the 
young participant, and necessary referrals made if sought.   In addition, the respondent will be 
informed at the outset that if issues arise during the interview that involve abuse or severe 
depression that may lead to the participant subjecting themselves or others to harm, the 
interviewer may have a medico-legal obligation to report to a counsellor, nurse or doctor 
while informing the participant. 
  
 
Similar to parents/legal guardians, the study participants themselves may be concerned about 
speaking to a stranger about very personal and very sensitive issues, mentioned above, and 
may feel particularly vulnerable without the parent/legal guardian during the interview.  Once 
again, as mentioned above, the counsellor that they are familiar and at ease interacting with 















be taken in allaying their fears and concerns as mentioned above. In addition, should the 
study participants feel the need for debriefing following one-on-one interviews or focus 
group participation, this will be provided by referral to either a counsellor or the facility 
social worker 
 
The parents/legal guardians and young study participants will be assured that although the 
benefits of doing the study may not be felt immediately, however, since a study of this kind 
has not been done before, the information gained will hopefully be used to inform policy.  In 
addition, health programmes will hopefully be developed that will address concerns and 
challenges highlighted in the study findings.  Also, since many of the care-givers are 
experiencing problems with their adolescents’ adherence now that they are old enough to take 
treatment on their own, programmes may be developed that will offer support to parent/legal 
guardians of ADLHIV.  Furthermore, since the adolescents are also attending school, which 
poses challenges of its own, with limited peer and teacher support, the findings can be used to 
get the Education Department’s buy-in to introduce support programmes in schools which 
will help towards adherence. 
 
Both the parents/legal guardians accompanying the adolescents and the study participants 
will be offered refreshments and transport money for participating in the study. 
 
In addition, as mentioned above, ethical approval for the study will be obtained from the 
UCT Health Sciences Faculty Human Research and Ethics Committee; and consent for the 
research will also be sought from the Western Cape Provincial Department of Health and the 






As mentioned earlier, since the adolescents are primarily Xhosa-speaking, and in order to 
avoid the “white coat” effect, each interview will be conducted by a trained 
fieldworker/interviewer in Isi-Xhosa and the researcher will not be present during the actual 
interviews. The fieldworker will be bilingual, have a bachelor’s degree or equivalent skills 
in the social or health sciences, in addition to experience in qualitative interviewing and 
working with youth.  We will use a training program used in qualitative methods training, 
usually used for other studies conducted in the Women's Health Research Unit (WHRU) at 
UCT, to conduct a 2-day training program for the interviewer/fieldworker. Training will 
focus on ensuring she/he has sufficient qualitative interviewing skills and on enhancing 
her/his knowledge of HIV, youth and ART.   Training will follow standard procedures such 
as: an explanation of the rationale behind the study, review of key principles underlying 
qualitative research methods and interviewing, familiarisation with the procedures for the 
study including procedures and practice for interacting with health service staff, and 
procedure for the importance of participants being enrolled with full informed consent. 
Training will be conducted by the PI, Dr Holele, with advice from A/Prof Diane Cooper from 
the WHRU at UCT. 
 
The researcher will therefore work very closely with a fieldworker, who is not only 
experienced in conducting qualitative interviews, but also trained to work with youth. The 
latter issue is especially important not only because the study participants are particularly 















Therefore the interviewer/field worker will need to be able to establish good rapport with 
each interviewee and thus create an environment that will put the interviewees at ease and 
encourage them to speak freely. For this reason, it will be very useful to also include one of 
the clinic’s youth counsellors, who is known to the study participants, as part of the team to 
assist during the interviews by acting as facilitator, especially since the researcher is also their 
doctor.   
 
The researcher will play the role of overall facilitator, overseeing the entire data collection 
process, and ensuring the proper use of the digital recording device.  In addition, the 
researcher will also be responsible for the following: (a) recruitment of study participants, (b) 
ensuring that there is written consent from the legal guardians of each study participant and 
that assent has been obtained from each study participant, (c) to ensure that the data 
collection instruments are functional and ready for use prior to each interview, (d) to oversee 
and supervise the overall data collection, transcription and translation process, since all of 
this will be conducted by the fieldworker, (e) training of the fieldworker and local assistant 
(clinic youth counsellor), to ensure clear knowledge and understanding of the aim of the 
research, the subject issues that will need to be covered, and in qualitative research 
techniques, (f) analysis of the data collected, transcribed and translated by the fieldworker. 
 
 
7.1 Logistical Challenges 
1.  Recruitment Challenges: 
(i) Getting the young adolescents to agree to participate in a study that involves the use of a 
recording device, especially the one-on-one interviews.  They may find this rather daunting.   
(ii) Getting consent from the participants’ care-givers. Given the sensitivity of the topic and 
the age and thus vulnerability of the study participants, caregivers might have reservations in 
having their children participate in a research study.  
(iii) Since many of the adolescents are old enough to come to the clinic unaccompanied, 
getting the caregivers to attend with them for the purposes of participating in the research 
study may prove fairly challenging and time consuming. 
2.  Communication Barrier 
Finding a fieldworker who is not only proficient in Isi-Xhosa, but one who is also able to 
interview young people and get them to freely discuss the issues around HIV and its impact 
on their young lives will pose a great challenge.  
3. Transcription and translation 
The process of first transcribing verbatim, and then translating the transcripts into English for 
ease of analysis will be very time consuming and costly. In addition, some of the gist of what 
is said may be lost during the process of translation. Therefore, due to time and financial 
constraints, the fieldworker employed may be called on not only to interview the study 
participants, but also to transcribe and translate the collected data material.   
4. Finding a quiet space in a very busy clinic where the interviews can be conducted in a 
manner that ensures privacy and confidentiality may pose a challenge.   However, since the 
clinic has a “chill room” for adolescents, this will probably be an ideal space to use, also 
because it is a familiar, comfortable and favoured space, it may assist in putting the study 





















8.0 Write-up and dissemination 
 
The research study outcomes will be of interest to the National and Western Cape provincial 
departments of health, the Department of Social Services and the Education Department.  In 
addition, it will also be of interest to health care providers involved in pediatric and 
adolescent HIV management specifically, NGO`s involved in the development of youth 
health promotion and prevention programmers and services, and finally, the study 
participants and especially the parents and legal guardians of HIV+ children and adolescents.  
 
The findings of this research will hopefully provide new insights into how young, perinatally 
infected ADLHIV view and understand their condition and the need to be on lifelong 
treatment.   In essence, their perspectives and attitudes and how that affects their ability to 
adhere to their treatment. The insights gained will hopefully guide future adolescent health 
planning and policies nationally.  At provincial level, it is hoped that the findings will provide 
health managers and health care providers with some guidance on novel ways of developing 
effective approaches to adolescent health promotion, prevention and service provision.  
Since HIV affects more than just the individual, but the family and ultimately the community; 
and since many of these children have lost parents and are raised by relatives, commonly 
grandmothers, hopefully the research data will highlight some of the concerns and challenges 
that these young adolescents face daily.  It is hoped that departments such as education and 
social services will join the health department in taking these issues into consideration during 
budget and resource allocation. 
The researcher will organise a meeting at the clinic to give feedback to study participants, 
their legal guardians and health care givers about lessons learnt. In addition, the findings of 
the study will be presented to other researchers during workshops and conferences to 
stimulate further research into the subject. And finally, the article will be prepared for 
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Part B: Structured Literature Review 
 
Introduction and Background 
 
Global HIV epidemic and adolescents 
 
The fastest growing population worldwide are the youth, age <25 years, who make up at least 
a fifth, of the world’s population.   Of the 1.2 billion young people between the ages of 15-24 
worldwide, an estimated 10 million are living with HIV (Wilson et al, 2010).  Furthermore, 
2.1 million children under the age of 15 are estimated to be living with HIV globally, the 
highest burden being in developing countries, where a significant number of children are 
living with HIV from perinatal transmission (Richter et al, 2010; WHO, 2009).   Thus 
globally, the prevalence of HIV among the youth (< 25), has reached staggering proportions.  
Furthermore, studies show that the global HIV epidemic is largely youth-driven, with the 15-
24 year age group bearing the highest burden (Wilson et al, 2010). In 2007, it was estimated 
that more than 1 million new HIV infections occurred among the youth between  15-24 years, 
which made up forty percent of all new HIV infections worldwide (Wilson et al, 2010; WHO, 
2009).  Sub-Saharan Africa is home to Sixty-three percent of the 15-24year olds living with 
HIV, i.e. 6.2 million (Wilson et al, 2010).    
 
A fair proportion of the youth between ages 15-24 years, fall under the category of 
adolescents
1
.  Eighty-five percent of the 1.2 billion adolescents
 
worldwide are located in the 
developing world (WHO, 2007).  Perkins (2001) describes adolescence thus: “Adolescence 
begins with biological maturation (puberty), when young people must accomplish 
developmental tasks and develop a sense of personal identity. It ends when young people 
achieve self-sufficient adulthood as defined by society” (Perkins, 2001, pg3).  Although the 
World Health Organisation (WHO) defines adolescence as those between ages 10-19 (WHO, 
2010), they can be separated into early adolescence (10-14yrs), middle adolescence (15-
17yrs) and late adolescence (>17yrs), (Perkins, 2001).  Despite this, there is a tendency in the 
literature to combine all adolescents into one homogenous group, those <15years and those 
>15years, with the <15year olds being combined with paediatric cases, especially when 
gathering statistics regarding HIV prevalence and treatment outcomes.   
 
In high-resource countries such as the United Kingdom, where ART has been available since 
1996, the benefits have long been realised, rendering the survival into adolescence of 
perinatally infected children, the norm (Hazra et al, 2010; Jaspan et al, 2009). While only 
~354,000 of the 2.1 million HIV infected children are on Antiretroviral treatment (ART), 
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leaving a disproportionately high treatment gap, (WHO, 2010), the survival of perinatally 
infected HIV+ children to adolescence is increasingly recognised in sub-Saharan Africa, as 
the HIV epidemic matures (Ferrand et al, 2009; Bakanda et al, 2011; Davies et al 2009).  In 
Southern Africa, perinatally infected children were not expected to survive beyond the age of 
5 years, and approximately 50% were expected to die before the age of two years without 
ART (Ferrand et al, 2009). However, with increasing accessibility of ART, current trends 
suggest that the epidemic is headed in the same direction as in well-resourced countries, with 
the first generation of perinatally infected children reaching adolescence (Souza et al, 2010; 
Ferrand et al 2009; Bakanda et al, 2011; Jaspan et al, 2009).   
 
The prevalence of HIV among children under the age of 15 years in South Africa was 
estimated at 2.5% in 2008, mostly from perinatal transmissions (Grey, 2009). The 
introduction and subsequent role-out of ART has led to a dramatic improvement in the 
survival rate of HIV+ children in this country, and has effectively changed the face of the 
epidemic among perinatally infected children (Hazra et al, 2010; Souza et al, 2010).  With the 
largest ART programme in the world to date in the country, approximately 32 000 children 
under 15 years were on treatment in 2007 (Davies et al, 2009). Furthermore, a study looking 
at treatment outcomes of HIV positive children who access ART under the age of 16 showed 
a 7.7% mortality and 81.1% retention in care 3 years following ART initiation (Davies et al, 
2009).  With the new National Department of Health ART Guidelines of 2010 (NDOH ART 
guidelines, 2010) rendering treatment immediately accessible to children <1 year, the above 
figures, especially the number of children on treatment, is expected to have increased 
significantly, although this may widen the treatment gap. 
In view of these findings, a new frontier of challenges, where this epidemic is concerned, has 
now been reached regarding this particular population.  Disclosure issues, adherence to ART 
and transmission of resistant HIV have become major concerns (Souza et al, 2010; Wiener et 
al, 2007). The latter two issu s especially, could potentially pose a serious public health 
challenge in the near future (Wiener et al, 2007).  
Objectives 
The objective of this literature review was to explore existing literature on experiences of 
adolescents living with HIV (ADLHIV), on ART, i.e. their knowledge, perceptions and 
attitudes towards HIV and how these impact on adherence.   
Methods 
Selection criteria for studies 
A review of the literature, published in English since 2000, which is when ART availability 
occurred in sub-Saharan Africa, was undertaken; and particular attention was given to 
research conducted in the context of sub-Saharan Africa. Studies reporting on psychosocial 
factors and how these impact on adherence were sought. To this end, 4 major themes viz: 















However, given the dearth in the literature in this sub-population, the initial search and 
inclusion criteria were broadened to include the following: (i) HIV infected and uninfected 
youth between the ages of <10-<24 years, with the search restricted to studies on impact or 
links with knowledge around sexual and reproductive health, including HIV, and/or 
adherence to ART. (ii) Qualitative and quantitative studies, with the latter restricted to studies 
with virological and immunological outcome measures in relation to adherence only. (iii) 
Both perinatally and behaviourally infected youth, with the latter also restricted to studies 
linked with knowledge and/or ability to adhere to ART. (iv) Literature on adolescent health 
such as development, and sexual and reproductive health (SRH), were included in as far as 
they were linked or showed impact on knowledge and/or ability to adhere to ART. Insofar as 
possible the focus was on younger adolescents. Studies were excluded if: the focus was on 
care-giver input on psychosocial factors and their impact on adherence, for children <15; in 




PubMed, and Google Scholar were searched for published peer and non-peer reviewed 
papers.  Key words for the search criteria included Adolescent, HIV, ART, adherence, 
disclosure, knowledge, perspectives, attitudes, and stigma. In addition,   reference lists of 
relevant peer-reviewed articles were hand-searched, to ensure comprehensive search of 
existing literature. Furthermore, literature from sites such as, the World Health Organization 
(WHO) and the Joint United Nations Programme on HIV AIDS (UNAIDS) were also 
included, for information on HIV epidemiology and progress thus far.  Abstracts were read 
and all the relevant articles were identified and retrieved, organized thematically, and then 
summarized. 
 
HIV knowledge among ADLHIV 
Given that the youth are the drivers of this epidemic, and most infection is transmitted 
behaviourally (Wilson et al, 2010; WHO, 2006), knowledge around sexual and reproductive 
health, including HIV transmission is paramount in prevention strategies. And yet, according 
to the most recent data, less than 40% of young people have basic information about HIV 
(WHO, 2009).  This assertion has been confirmed by studies on adolescents in low/middle 
income countries, which also revealed gaps in knowledge around sexual and reproductive 
health (SRH) issues and HIV transmission (Bakeera-Kitaka et al, 2008; Undie et al, 2007; 
Jaspan et al, 2009).      For instance, a study by Chacko et al (2007), looking at knowledge 
and perceptions about STI’s and pregnancy among Ugandan youth between the ages of 14-18 
years, found a general lack of knowledge about the association between HIV/AIDS and 
pregnancy.  Study participants also demonstrated a lack of understanding of the importance 
of dual protection against HIV transmission and pregnancy through the combination of 
condom use and contraceptive pill/injection. Similarly, a study by McMannus et al (2008) 
looking at knowledge, perception and attitudes among Indian girls between ages 14-19 years 















and 21% believed that the contraceptive pill was effective in preventing HIV infection. Both 
these studies, however, only looked at uninfected adolescents ≥ 14years. To date, there is 
limited data concerning the young adolescent sub-population, especially in sub-Saharan 
Africa, regarding knowledge around HIV/AIDS and SRH. Furthermore, knowledge among 
young ADLHIV remains largely unexplored.  However, there is some evidence that even 
among ADLHIV, gaps and misinformation also exists.  A study by Bakeera-Kitaka et al 
(2008), conducted on HIV+ youth between ages 11-21 in Uganda, examining sexual and 
reproductive health needs, as well as determinants of sexual risk-taking among young people 
with HIV, also found knowledge gaps among their study cohort in the areas of reproductive 
health, HIV transmission, and family planning.  In addition, there were misconceptions 
regarding HIV transmission among the participants, such as: “young children could not get 
HIV by having sex with an adult” (Bakeera-Kitaka et al, 2008, pg 428). However, according 
to the study findings, there was some appreciation regarding HIV re-infection and the risks it 
carried for them in terms of their health (Bakeera-Kitaka et al, 2008). Once more, although 
the study population age range included young adolescents, the mean and median age of the 
participants was 16 years. 
 
Misinformation, although considered harmless in certain cases, has a tendency to inform an 
individual’s notion of reality (Chacko et al, 2007).   The maxim ‘Knowledge is power’ rings 
true, especially when it comes to equipping young people to make informed decisions 
regarding their sexual health (McMannus et al, 2008).  Based on the above findings, it can be 
surmised that in order to stem the tide of high HIV transmission among the youth, and 
especially secondary transmission by ADLHIV, there is a need to address the SRH 
knowledge issues while they are pre-pubescent and prior to their sexual debut. A good first 
step would be by examining how knowledgeable young ADLHIV are regarding SRH issues 
and HIV transmission and re-infection.  This is one of the key aims of the proposed study.  
 
 Adolescents’ experiences of living with HIV 
The effects of the HIV pandemic on children have been substantial, especially in terms of 
loss of parents and subsequent income. To date, approximately 15 million children have lost 
either one or both parents to AIDS, resulting in major disruptions in children’s lives (Richter 
et al, 2010).  Thus many ADLHIV face the double burden of not only being HIV+, but also, 




In addition, the impact of HIV on growth and development, such as: delayed puberty and 
stunted growth, (Buonoro et al, 2008; Kekitiinwa et al, 2008; Spiegel and Futterman, 2009) 
neurological, and language deficits, (Van Rie et al, 2008), and psychiatric illness, commonly 
anxiety and behavioural disorders (Foster and Fidler, 2010) have been demonstrated. 
However, findings of neurological and cognitive deficits, were more common among young 















of HIV+ Ugandan children between ages 6-12yrs, found no significant difference in 
neurologic and cognitive assessments between this cohort compared to HIV- negative 
controls (Bagenda et al, 2006).  In essence, HIV+ adolescents have normal information 
processing abilities (Bagenda et al, 2006).  This bears remembering, especially considering 
that the young adolescent should be targeted for behaviour modification interventions, such 
as SRH education, prior to their sexual debut, in order to achieve effectiveness in stemming 
the tide of the spread of HIV among the youth and the relevance to the age group in our 
study.   
 
Globally, studies on chronic illness in adolescents have shown the negative impact of ill-
health on the physical, emotional, social and cognitive development of adolescents (Forinde 
et al, 2008).  Hence, for perinatally infected children, the implications are that as they 
transition into adolescence, they face increasing difficulties in their attempts to negotiate and 
reach various psychological, biological and cognitive developmental milestones. They have 
the added burden of having to cope with a health condition that still carries with it a high 
degree of stigma.   
Psychosocial wellbeing 
Stigma shapes attitudes and perspectives around HIV and towards those living with HIV. A 
study done by Ayres et al,( 2006), looking at the psychosocial well-being and health care 
needs of young people between 10-20 years, found stigma to be a recurrent issue that arose 
among the respondents with regard to their experiences as ADLHIV (Ayres et al, 2006). This 
points to a need for more community directed intervention programmes to improve attitudes 
around HIV and those living with the disease.  To this end, a study by Stephenson et al 
(2009), looking into how the community environment shapes the HIV/AIDS attitudes of 
young people (ages 15-24) in 3 African countries showed that: “Young people with higher 
knowledge of transmission routes for HIV had more supportive attitudes towards those with 
HIV” (Stephenson et al, 2009, p.3). Therefore, how adolescents experience HIV, their 
attitudes and perspectives are significantly shaped by their social and economic environments 
(Stephenson, 2009).  
Very little research has been conducted among adolescents and their perspectives on the issue 
of stigma and how that affects their experiences, much less among young adolescents. A 
study by Strydom and Raath (2005), examining the effects of community attitudes found that 
most ADLHIV experienced rejection and gossip.  In addition, a study by Li et al, (2010), on 
ADLHIV between the ages of 7-15 years, revealed that adolescents viewed HIV as physically 
and emotionally painful.  Furthermore, some reported verbal and physical abuse by peers and 
care-givers; however, they regarded strong family and friend support systems as positive 
aspects of their lives (Li et al, 2010). These are some of the limited studies conducted, 
examining experiences among ADLHIV in sub-Saharan Africa, especially among the 
younger age group. However, additional research is required in this sub-group of younger 
adolescents living with HIV. This links well with my study aims to gain insights into their 
experience of HIV and ART, i.e. attitudes and perceptions and how these impact on their 
















4.  Disclosure issues among ADLHIV    
HIV status disclosure remains one of the most complex and emotive subjects among those 
affected and infected.  The stigma and discrimination associated with HIV, still prevalent 
even in highly affected communities, adds to the complexities around the issue (Stephenson 
et al, 2009).  
 
Timing of disclosure 
The dilemma of when to disclose and how to disclose and the psychosocial impact the news 
may have on the child/adolescent are usually what makes it such a daunting task, thus the 
reluctance on the part of the care-givers, and even health care givers to disclose their status to 
them (Vujovic et al, 2010).  Consequently, studies on disclosure have shown that the number 
of children and adolescents who are disclosed to, vary. For example, a study by Vaz et al 
(2010) in the DRC, examining disclosure issues, found that of the 259 HIV+ adolescents 
between the ages of 8-17 screened, only 8 (3%) had been disclosed to and were thus eligible 
for study participation. Similarly, a study by Souza et al (2010), examining outcomes of 
perinatally infected adolescents between 10-19years found that out of a total of 49 study 
participants, only 31(63%) had been disclosed to.  A similar study looking at treatment 
outcomes of perinatally infected children who had initiat d treatment between 2003-2005 
found that only 12 (7.9%) knew their status; and of the 12, only 3(25%) of the 9-11year olds 
and only 5(83%) of the 12-15year olds  knew their status(Reddi et al, 2007). Despite these 
low levels of disclosure to those in the younger age group, the consensus, based on studies 
done in the United States, is that 8-10 years is considered an acceptable period (Hazra et al, 
2010). 
 
Many care-givers are reluctant to disclose to their perinatally infected children.  Apart from 
unease about the infected child's readiness, many cite factors such as: (i) fears that the child 
might reveal their status to others with negative consequences, such as ostracism, (ii) 
concerns about how disclosure might affect the parent-child relationship (e.g. anger towards 
the parent) (iii) and anxiety regarding the child’s emotional reaction (Vujovic et al, 2010; 
Wiener et al, 2007).  However, in a systematic review by Wiener et al (2007), looking at 
research on disclosure rates and correlates and also the psychological impact of disclosure or 
non-disclosure among perinatally infected adolescents, one study found that of the 99 parent-
child dyads interviewed on disclosure, the average age of disclosure was 7.5 years.  
 
With regard to the psychological impact on perinatally infected children and adolescents, the 
systematic review by Wiener et al (2007), showed that the psychological outcomes following 
disclosure varied among the different studies.  Nonetheless some studies have shown that 
disclosing a child’s HIV+ status to them is beneficial not only to the child but to the care-
giver and even the health-care providers looking after these children (Souza et al, 2010).  
HIV sero-status disclosure has been found to decrease anxiety, depression and behavioural 















been disclosed to around age 7 years, in one study, 65% were happy with the timing of their 
disclosure while 86% felt that disclosure was done by the ‘right’ person (Wiener et al, 2007).  
 
The process of disclosure  
The literature supports disclosure as a process rather than a once-off event (Vujovic et al, 
2010; Wiener et al, 2007).  However, a study by Vaz et al (2010), looking at experiences of 
HIV+ adolescents between the ages of 8-17 years, with regard to disclosure revealed that 
most of the adolescents’ experience of disclosure by care-givers was a once-off event rather 
than a process.  The participants in this study reported that little was done to prepare them for 
the news and little was said afterwards in terms of discussion around the issue. In addition, 
many were left with unanswered questions about how and why HIV infection occurred and 
HIV progression.  The study reveals that most of the information given was tailored to 
emphasise the need for good adherence. Furthermore, adherence to medication was also cited 
by care-givers as the motivation for them to disclose, along with concerns about sexual 
transmission to potential partners as they got older (Vaz et al, 2010).   
Although there is a belief that disclosure is a good strategy to enhance treatment adherence 
because there is better understanding of the need for ART, and also, trust is built, research on 
disclosure and adherence is inconclusive (Wiener et al, 2007).  On the whole there is a dearth 
in the literature around the emotional and psychological well-being of children post-
disclosure of their HIV status (Vujovic et al, 2010; Vaz et al, 2010). In fact, few studies have 
looked at circumstances surrounding HIV sero-status disclosure to adolescents, fewer have 
done so in resource limited settings, and even fewer involving young ADLHIV giving 
account of their experiences regarding the issue (Vaz et al, 2010). This points to a need for 
this kind of information to help inform interventions. The proposed study aims to contribute 
to filling this gap.  
 
5.  Adherence and adolescents 
As perinatally-infected ADLHIV mature into adulthood, they face a myriad of challenges 
which have now come to the fore, posing serious dilemmas for ADLHIV, their care-givers 
and health carers.  (Souza, et al, 2010; Strydom and Raath, 2005; Li et al, 2010; Vaz et al, 
2010; Nachega et al, 2009; Williams et al, 2006 ).  Maintaining good adherence is a challenge 
among adolescents as they grow older, as shown in a study looking at predictors of adherence 
to ART among vertically infected children and adolescents between the ages of 3-18 years.  
The study revealed a decline in adherence rates with age, and the 15-18 year olds had the 
worst adherence (Williams et al, 2006).   According to established ART guidelines, 
adherence to ART needs to be >95% consistently to ensure good outcomes in ART (Murphy 
et al, 2003).  A study by Nachega et al (2009) of adolescents between ages 11-19 years 
showed that ART adherence among adolescents was significantly lower than that of adults, 
which led to poorer virologic and immunologic outcomes. The literature recommends good 
adherence to antiretroviral therapy to ensure good virological outcomes and less risk of viral 















options as adolescents mature into adulthood, adding to the individual clinical and public 
health concerns about this emerging population (Murphy et al, 2003; Wiener et al, 2007).  
High pill burden and complex ART regimens make maintaining >95% adherence difficult 
(Murphy et al, 2003).  A study looking at adherence barriers among adolescents with 
behaviourally acquired HIV cited forgetfulness and changes in daily routine as the most 
common reasons given by participants for non-adherence (Murphy et al, 2003). Studies 
conducted among perinatally-infected ADLHIV found similar factors to impact on adherence 
(Nachega et al, 2009).  The study recommends improving ADLHIV’s organisational skills as 
an adherence facilitating strategy, which has been found very effective in children with 
chronic diseases e.g. Diabetes Mellitus (Murphy et al, 2003). Given the increase in survival 
of HIV-infected adolescents on ART, it is becoming increasingly important to identify 
barriers to adherence in this population in order to design appropriate and effective 
interventions.  However, research in this area thus far has been fairly limited, especially in 
sub-Saharan Africa (Nachega et al, 2009), particularly among young adolescents.  In 
addition, the young ADLHIV’s views, knowledge and perspectives on the need for life-long 
ART remains largely unexplored, thus this study - extending experience of HIV to experience 
around life-long ART, and how they feel about this as their reality.   
Conclusion 
There is a real paucity in research data on how the young HIV+ adolescent experiences HIV 
and ART; what their knowledge, understanding and views are, how socio-cultural influences 
impact on adherence and finally, how they see the future.  Even more importantly, this area 
of research, on the young, perinatally infected HIV+ adolescents (<15years), remains fairly 
neglected in sub-Saharan Africa. The focus, so far, has been on adherence in association with 
virologic outcomes, or care-giver characteristics and influences.  Perhaps it’s the fact that 
their age and therefore vulnerability as potential research participants poses serious ethical 
challenges.  That, and also the need for special techniques and provisions upon their inclusion 
in research, has added to the reluctance to recruiting them as study participants.  However, 
due to the serious individual, clinical and public health implications of possible resistant HIV 
transmission by these adolescents, there is a need to address the above issues while they are 
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As perinatally infected adolescents living with HIV (ADLHIV) grow older and gain a greater 
sense of independence, disclosure issues and adherence to antiretroviral treatment (ART) 
have become major concerns. However, research on how adolescents view and cope with 
these challenges remains limited, especially in Sub-Saharan Africa.  We explored ADLHIV’s 
understanding of their infection and its perceived effects on their wellbeing, and ultimately, 
on their attitude towards life-long adherence to ART. 
 
Methods 
A total of 24 perinatally infected male and female ADLHIV, aged 10-15 years, attending an 
adolescent ART clinic in South Africa, was included in this exploratory study. 12 in-depth 
qualitative interviews and 2 focus group discussions, were conducted.  Qualitative data were 
analyzed using grounded theory.  
 
Results 
Most of the adolescents demonstrated good knowledge and understanding around HIV, how 
it affects their health and the need for life-long ART. There was general acceptance, but also 
occasional resentment, anger and frustration regarding HIV and the need for life-long 
treatment.  Nonetheless, their experiences were mostly positive, despite the negative effects 
of stigma and community attitudes.  Knowing that there are others like them, also had a 
significant impact on how they experienced HIV. Many expressed appreciation for the effects 
of ART in keeping them healthy, allowing them a normal life and hopefulness about the 
future.  
Conclusion 
Despite the challenges of living with HIV, adherence being the major one, most of the young 
adolescents showed good insights regarding the need for life-long ART and genuine 
motivation to remain adherent.  
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The survival of perinatally infected HIV+ children to adolescence
2
 is increasingly being 
recognised in sub-Saharan Africa, as the HIV epidemic matures [1-4].   In South Africa, with 
the largest ART programme in the world to date, approximately 32 000 children under 15 
years were noted to be on treatment in 2007 [3].  A South African study looking at treatment 
outcomes of HIV positive children who access ART under the age of 16 showed 7.7% 
mortality and 81.1% retention in care, 3 years following ART initiation [3].  This study 
suggests that similar to the developed world, the first generation of South African perinatally 
infected children are growing into adolescence with the need for life long antiretroviral 
therapy [1-2, 5- 6].  
 
Adolescence is characterized by many complex changes, such as cognitive and emotional 
maturation, usually preceded by physical and sexual maturation [7].  In addition, this 
developmental phase also includes development of identity, adapting to new social roles and 
the intricacies of autonomous decision-making.  Adolescents are also prone to risk-taking and 
impulsive behaviour, [7-8].  The latter two developmental challenges render adolescents 
vulnerable to sexually transmitted infections (STIs), including HIV, and unplanned 
pregnancies [9-11].  Furthermore, adolescents with chronic diseases such as HIV, in addition 
to the above-mentioned challenges, are expected to assume greater and greater responsibility 
for their disease management as they grow older and gain a greater sense of independence.  
Moreover, they have to make decisions about disclosure to peers and sexual partners, and risk 
the possibility of rejection and/or stigmatisation, challenges that tend to impact negatively on 
their adherence [12-13].  In this regard, studies have revealed a decline in adherence rates 
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with age, among adolescents on ART, with the 15-18year olds having the worst adherence 
[14-15], leading to poor immunologic [15] and virologic outcomes [15,4].  The factors 
mentioned above pose challenges to successful HIV and ART management in this emergent 
population, failure of which could have significant individual, clinical and public health 
impact [13].  For that reason, how adolescents view and cope with these challenges in the 
worlds that they live in necessitates further studies [13]. In addition, it is important to identify 
barriers to adherence in this population in order to design appropriate and effective 
interventions.  However, research in this area thus far has been limited, especially in sub-
Saharan Africa [15]. Adolescent HIV research has been conducted mostly among adolescents 
in developed countries, and the majority of those studies have focused on older adolescents 
(>16yrs) with behaviourally acquired HIV [14].   
 
The primary aim of this study was to attempt to see HIV through the eyes of young (<16 
years), perinatally infected adolescents living with HIV (ADLHIV). We explored adolescent 
understanding of their infection and its perceived effects on their wellbeing. Also, we 
explored ideas of HIV treatment and the impact of the disease on their social lives and peers. 
Given the gendered nature of the HIV epidemic in sub-Saharan Africa, gender issues and 
cultural influences and how these factors impacted on their experience of HIV were also 





















In-depth interview guides, focus groups interview guides and a field-diary were used as data 
collection tools.  The main data collection technique used was in-depth, semi-structured, 
open-ended interviews. In addition, two focus group interviews were also conducted, on male 
and female adolescents between the ages of 10-15 years.  The participants chosen for focus 
group interviews were a different sample, to increase the number and diversity of opinions.   
 
Purposive sampling, common in qualitative research entailed sampling those from whom it 
was felt we would gain the most insights. Written consent to participate, and for the use of an 
audio-recorder during the interviews, was obtained from the legal guardians of each of the 
study participants, in addition, assent was obtained from all the study participants. Ethical 
approval for the study was granted by the University of Cape Town Health Sciences Faculty 
Human Research and Ethics Committee, in addition, consent to conduct the research was also 
granted by the Western Cape Provincial Department of Health, the Gugulethu Community 
Health Centre/Hannan Crusaid Antiretroviral clinic.   
 
The interviews were conducted at the Hannan Crusaid
3
 antiretroviral (ARV) clinic, in a 
private counselling room, during the adolescents’ clinic visits.  Interviews were conducted by 
a trained fieldworker who was not involved in the adolescents’ health care in any way, were 
in Isi-Xhosa, the first language of respondents, and lasted approximately one hour.  Each 
recorded interview was transcribed and then translated verbatim into English, for ease of 
analysis.  
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A pilot study of five interviews, among respondents not recruited for participation in the 
actual study, was conducted in same facility by the researcher together with a trained Xhosa-
speaking fieldworker, to test the overall feasibility of the data collection methods and the 
study instruments. 
 
 A grounded theory approach was used to analyse the data. During data analysis, there was a 
search for core meanings, opinions, thoughts, feelings and behaviour of the interviewees.  
This was followed by an interpretation of the study findings, to demonstrate how themes 
related to one another and ultimately how concepts answered or responded to the original 
study questions.  Triangulation was used to ensure rigor, by comparing findings with existing 
data [16].   The researcher did not conduct the interviews due to a possible ‘white coat’ 
effect. The research constantly reflected on the data during analysis and consulted others to 
ensure reflexivity to take due note of her the influence of her role as the attending doctor. 



















A total of 24 ADLHIV, between the ages of 10-15 years participated in the study. 12 
participants were interviewed, and each focus group consisted of 6 participants. The majority 
of the participants were female (63%), and the mean age of the participants was 12 years.  
Results are reported as common to participants in both the individual interviews and the focus 
groups.  Where differences emerged these are specifically noted in the results. Participants’ 
views, perceptions and attitudes did not appear to be influenced by either gender or age, but 
seemed to arise rather as a consequence of how information was gained and processed. The 
data is presented according to the major themes that emerged from the interviews and focus 
group discussions. 
1. Knowledge  
Most of the participants had some knowledge of HIV prior to knowing their HIV+ status, 
although for some, the first time they heard about HIV was at home, at the time their disease 
was disclosed.  Sources of information included school, the media, or the health care facility 
that they attended regularly, i.e. Hannan Crusaid ARV clinic, but for most, most of the 
information around HIV was acquired primarily from their schools:  
“I first heard about it in school, from my teacher.  She was saying you get it through 
blood, when you have sex without a condom, when you touch someone without gloves 
and when you use someone else’s toothbrush” (part. 2: 10yo F).
4
  
On the whole, the participants demonstrated a broadening of their knowledge thereafter.  
Types of knowledge included: HIV as a life-long infection was commonly understood among 
most; a few showed an understanding of the difference between HIV and AIDS; another 
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common theme was the importance of and need for anti-retroviral therapy (ART) and its 
effectiveness against HIV progression.  There were some who displayed an understanding of 
the pathogenesis and transmission, information acquired mostly in their clinic support groups: 
“It [HIV] can do something to your body if you don’t take your medication.  It can 
attack “amajoni emzimbeni”
5




For many, the information acquired was accurate. However, a few showed poor knowledge or 
confusion.  One participant seemed confused about HIV and TB and talked about the two 
conditions interchangeably. In contrast, when asked about general knowledge of peers, most 
of the participants from the focus groups felt that young people in the community and even in 
schools had limited knowledge around HIV/AIDS.  Many of the participants concurred that 
the support groups that they attended when they came for their clinic visits helped in ensuring 
that they were better informed, compared to their peers. 
The descriptions among the participants in the individual in-depth interviews, when asked to 
visualize HIV and its effects on the body, varied considerably.    Some described HIV as 
round big and black, or umoya
7
, invisible inside the body but harmful.  All associated HIV 
with harmful health effects: 
“I picture something that looks strange, that has dirty things on it….well it kills your 
body cells….it fights with your body cells.  HIV is dirty.  Your body cells protect you.  
So HIV brings the virus. Your body cells fight it when you take the medication” 
(participant 4:13yo F). 
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  “Amajoni emzimbeni”, also sometimes referred to as “soldiers of the body or body cells”, means immune 
system, a phrase commonly used in the clinic when educating patients on the ill-effects of HIV on the immune 
system. 
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grp 1 or 2 participant, e.g. (participant 4: 13 year old Female, abbreviated in the text as:  part4: 13yo F [2]) 
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2.  Disclosure 
Many recall being disclosed to between ages 7-10 years. Most of the participants had their 
HIV+ status disclosed to them by their care-givers, commonly mothers, at home, and with 
another relative present.  Participants surmised that their caregivers had disclosed their HIV 
status to them at the time they did: (a) to promote understanding and general tolerance of 
those living with HIV, or; (b) due to encouragement from health care workers, or; (c) due to 
curiosity expressed by the participants regarding the need to either continue taking 
medication for unknown reasons or need for repeated clinic visits. However, in some cases 
the participants suspected their diagnosis prior to being disclosed to:  
 “When they were showing treatment on TV, I realized that it looked the same as mine.  
I suspected that I also had HIV.  So I started asking my mom why I was taking this 
treatment.  I wanted her to tell me. I just wanted to know” (part. 1:13yo F). 
Participants reported that the information communicated, when they were being disclosed to, 
emphasized the importance of good adherence. A common theme that also emerged was that 
many of the care-givers were forthcoming about how the participants acquired their HIV 
infection.  A few were given mixed messages, by initially being told that they have TB. 
Participants recalled the moment of diagnosis disclosure with sadness, with many tearful 
during this part of the study. All the participants described negative reactions, most 
commonly, emotions were sadness, coupled with shock, fear, disbelief, anxiety that they were 
going to die, or resignation. In contrast, others, albeit distraught, took comfort in the fact that 
they were on ART and doing fine.  Another participant stated:  
“….I went to the bedroom and cried because I was scared, thinking that HIV was going 
to kill me.…. I didn’t know what it was…. I asked why did I get HIV, why?  I closed the 
door and cried…I thought that HIV was on the food” (part 3: 13yo F [1]).  Despite the 















There also seemed to be an unspoken element of resentment, especially among some of the 
younger participants, directed either towards HIV’s deleterious health effects and the real 
possibility of death, or perceived betrayal by those who had kept this illness a secret from 
them:  
“…I was thinking, why my mom never told me [participant very teary at this point]…I 
asked him [the father who was disclosing to her] why they didn’t tell me earlier that I 
had HIV.  He told me that the doctor said I was not supposed to know.” (part. 2: 10yo 
F). 
Disclosure to others by the participants was also discussed.  Among the group, disclosure to 
teachers was most acceptable as they were trusted and supportive.    One participant disclosed 
to his teacher because he didn’t want the teacher to make a fuss when it was time for him to 
come to the clinic (F/N 1)
8
.  Many of the participants stated that they preferred to disclose 
only to friends that they know to also be HIV+.   Although some participants reported 
disclosing to trusted friends, many others expressed very strong reservations regarding 
disclosure to their peers or even close friends.  Apart from confidentiality and stigma, fears of 
rejection and ridicule commonly emerged as the biggest deterrents of disclosure to friends: 
“The reason that I don’t want to say anything is because it will spread.  The whole 
school will know that I have HIV.  I will hear them talking about me.  Even in the 
community, they will then know that someone in the street has HIV.  Maybe your 
mother’s friends will say: ‘don’t play with that child’”. 
Nonetheless, several of the participants from the focus groups expressed confidence in their 
friends and felt that their friends would support them if they were aware of their status. 
However, they wanted their friends to hear about their HIV+ status from them, rather than 
someone else.  
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3.  Experience of HIV 
The issue around community attitudes and the impressions and impact on these ADLHIV was 
explored in the focus groups.  Participants reported that what was commonly encountered:   
“….  In the taxis, they just accuse ‘Ow wena une-HIV! [Oh, you have HIV!]’….. (part. 
2:11yo F [2]). 
Teachers and those in the clinic encouraged them to “live positively”.  Participants felt that if 
the community were better informed, it would be easier to “live positively”; and that perhaps 
HIV/AIDS education in the community could cause a change in attitudes and perceptions, 
and lead to less stigmatization of those living with HIV.  Some suggested that their clinic 
counsellors should do some community education (F/N 1).    
Most of the participants reported a change in their own feelings as time progressed, becoming 
more accepting and positive since gaining awareness of their HIV+ status:   
“I feel alright, I’m like other children.  Because I am also healthy, I take my medication, 
they make me healthy” (part. 4:13yo F). 
What also emerged was the marked difference in the participants’ feelings once they 
discovered that they were not alone, that there are others their age, that are also living with 
HIV. Most appeared to take comfort in knowing that there were other adolescents who were 
going through the same challenges of living with HIV, such as the need for regular pill-
taking. Also noted, was the impact that the adolescent clinic the participants attend in 
particular, appeared to be having on how they experience HIV.  They no longer felt isolated:  
“It makes me happy.  I used to think I was the only one who has HIV.  So, I saw at the 
group [in the clinic] that there are others as well.  So it makes me happy.  I can talk 















bodies……we talk at the clinic in a support group.  We are all HIV+.  You get to talk 
about stuff bothering you” (part 9:14yo M).   
 Evident among the participants (who are also fellow clinic attendees) was the existence of 
trust when around each other.  Focus group participants described a particular code of 
conduct among them to maintain confidentiality, especially outside the clinic in the 
community, because of the stigma associated with HIV/AIDS.  
4.  Adherence 
Insight regarding adherence was noted to be good among all the participants, in that they all 
displayed good intentions and a sense of responsibility towards maintaining good treatment 
adherence, even though they weren’t always successful. Most were honest about forgetting to 
take their treatment occasionally, and stated that they simply forgot. Many barriers to 
adherence emerged that have been reported elsewhere and are therefore not new insights [12, 
15, 19], (see Appendix 2).  
Understanding of the value of antiretrovirals was eloquently expressed: 
“They are helping to fight the virus and stop it from spreading throughout your 
body”…and the bad thing about NOT taking ART: “You’ll be letting the virus spread on 
your body.  Even when you don’t take them on time, the virus gets a chance to spread in 
your body and it does as it pleases.  So you need to always take them at the same time 
every day”.  As for the good things about NOT taking ART…to that she answered “None”. 
(part.1:13yo F).  Many felt the same way. 
Positive attitudes emanated from the effectiveness of ART that is their reality currently.  
Reasons most frequently given by participants as their motivation for continued adherence 
were, the fear of becoming ill and sheer acceptance of their HIV+ status.   Some, however, 
expressed the fear of death from HIV and its health effects, a fear shared by many, coupled 















“Yhooo, I get angry and sometimes refuse to take pills.  I just throw them behind the 
cupboard….I always drink pills.  I’m supposed to be taking them always.  So, I want to 
stop taking pills, but I can’t because it’s here always…..HIV.  It’s always in the body” 
(part.9: 14yo M). 
The question of alternatives to ART was dealt with specifically in the focus groups. 
Participants were asked specifically about alternatives to ARV’s for HIV treatment, e.g. 
traditional medication, holy water or praying for the virus to go away. Most of them 
responded by saying “ayikho” –“No”.   There was consensus that ART was the only effective 
treatment.   Participants also spoke of their hopefulness for the future. This will be dealt with 


















This study, to my knowledge the first of its kind in this environment, shows that despite the 
challenges of living with HIV, adherence being the major one, most of the young adolescents 
have good insights regarding the need for life-long ART and genuine motivation to remain 
adherent.  Gratifyingly, these adolescents were forthcoming in their ideas and opinions, and 
showed a depth of understanding of the complexities of HIV/AIDS and its effects on their 
health.  In addition, their views, perceptions and attitudes did not appear to be influenced by 
either gender or age, but seemed to arise rather as a consequence of how information was 
gained and processed from various sources such as the media, school and their clinic support 
groups. This, however, could be a factor of their age, gender becoming a more important 
variable beyond age 14 years. 
 
Some of the participants demonstrated an understanding of the pathophysiologic processes 
involving HIV and the effects of ART.  Moreover, the adolescents’ perceptions and 
understanding of the effects of ART on HIV progression and on their overall health were 
good.  Many were able to demonstrate an amazing degree of understanding and insight 
regarding the significance of good ART adherence in relation to HIV progression. The 
reasons for the need to remain on treatment, and the fact that it’s life-long, seemed well 
understood and generally accepted, even though many did not find it easy or even pleasant. 
On the whole, the adolescents demonstrated that knowledge of pathophysiology contributed 
to real understanding of the need for life-long ART.  However, since this study did not link 
responses to actual outcomes, a pronouncement on whether this knowledge translates into 
better adherence cannot be made.   Further studies looking into whether this kind of increased 
















Furthermore, these findings are in contrast with findings of previous studies showing 
knowledge gaps among adolescents, around SRH and HIV [9, 11, 17].  It may be argued 
however, that the degree of knowledge displayed by these adolescents could be because the 
majority of the participants subsequently learned more about HIV prevention, transmission, 
progression and the effects of ART on HIV once they started attending the adolescent clinic 
and support groups at Hannan Crusaid ARV clinic, where open dialogue and information 
sharing around these issues are encouraged, under the supervision and guidance of trained 
youth counsellors. A study by Bagenda et al [18] showed that HIV+ adolescents are inclined 
to have normal information processing abilities.  This assertion tended to be confirmed by the 
data from this study cohort, with participants demonstrating knowledge and understanding of 
HIV, especially when they started attending the adolescent support groups.  This bears 
remembering, especially considering that where sexual and reproductive health behaviour 
modification interventions are concerned, focus needs to shift to include young adolescents, 
prior to their sexual debut, in order to achieve effectiveness in stemming the tide of the 
spread of HIV currently evidenced among the youth. 
 
In keeping with other findings [15, 19], but contributing new insights from perinatally 
infected ADLHIV, participants cited factors such as forgetfulness, busy schedules, 
interruption of daily routine and stigma as reasons for poor adherence.   However, by 
demonstrating capabilities of not only including pill-taking in their escalating social agendas, 
but also having clear plans on how they would do so outside the home, especially among 
peers who don’t know their status, suggested good foresight and commitment.  Yet, the 
occasional resentment, anger and frustration at having to take medication all the time needs to 















ART in keeping them healthy and allowing them a normal life, as observed by others [20-21], 
needs to be built on. This is likely to also have contributed to their positive attitude to living 
with HIV, despite the negative effects of stigma and community attitudes.  Moreover, their 
adolescent clinic support groups seemed to be providing them with an environment that 
turned what would have been an isolated and burdensome existence into a shared experience 
and a sense of camaraderie, once they discovered that they were not alone in living with HIV.  
Positive aspects of taking ART appeared to be strongly linked with their clinic support group 
experiences.  This is in keeping with findings by Li and colleagues [20], on adolescent needs 
and experiences, in which study participants also cited clinic support groups as one of the 
positive aspects of living with HIV; which further highlights the need for this intervention as 
part of the adolescent health services package. 
 
With regard to disclosure, participants’ responses illustrate the complexities around paediatric 
HIV disclosure.  Although all the study participants knew their HIV+ sero-status, having 
been disclosed to by age 10years as per clinic policy, some still felt this was too late. The 
danger of unduly delaying disclosure is that the child might find out another way, which 
could have deleterious outcomes, such as broken trust, and may lead to resentment, as 
demonstrated by some of the study participants. Nonetheless, in keeping with other studies, 
adolescents valued being informed in a manner that is clear and appropriate [21-22].  In 
addition, they appreciated family support [20-21] showing the pivotal role of the extended 
family as support structures, during disclosure, and also as adherence facilitators.   
 
Participants all seemed to share the same dilemmas and fears around trust, stigma and 
maintaining their friendships; balanced against facing possible rejection and 















issue of HIV in the community openly, is shown elsewhere too as a survival strategy against 
stigmatization [21].  However, despite the above misgivings regarding disclosure, a salient 
theme that emerged, was the support many felt they would get from their friends if they 
disclosed to them, and that they would prefer to be the ones who inform their friends of their 
HIV+ status. Support and guidance for adolescents, in this regard, needs to be looked into. 
In terms of socio-cultural influences, all the participants were very clear on the issue of ART 
as the only effective medication for HIV, and that there is no other alternative.  Finally, 
similar to other findings [20, 21, 23], participants were hopeful about the future, and many 
expressed desires to get married and have children.  However, given the complexities of 
disclosure, many felt it would be easier to have relationships with partners who are also living 
with HIV.  This is refered to as sero-sorting for partners, and is also shown in other studies. 
 
The limitations of this study were that: (a) the study population is not intended to be 
representative of the larger HIV+ adolescent population in South Africa.  The study 
participants all attend a Primary level ARV clinic with a special focus on youth-friendly 
services approach, as such, these adolescents have had very specific youth-friendly inputs, 
including trained and dedicated youth counselors, and may thus not be representative of other 
adolescents in general care clinics. (b) the structured support groups, which clearly had a 
significant impact on the adolescents’ experience of living with HIV, do not occur in most 
facilities with ADLHIV.  The strengths of the study were that (a) it gave voice to a largely 
overlooked sub-group of youth living with HIV, (b) In this setting, these adolescents 
demonstrated a very good understanding of their illness, and in many cases a well-adjusted 
attitude to their HIV infection and the need for ART.  They also showed good understanding 
of the reasons why treatment is needed.  This indicates that this can be achieved even at 
















Whilst this study indicates a pleasing level of understanding, positive attitude and acceptance 
among young adolescents born with HIV and now attending clinic for antiretroviral therapy, 
it doesn’t give any indication that this level of understanding translates into better adherence 
and better outcomes longer term.  Further studies, specifically looking at this, are 
recommended. In addition, data such as this may be used in formulating interventions that 
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The study population will come from the Hannan Crusaid adolescent ARV clinic, which is 
part of the Gugulethu Community Health Centre.  Gugulethu is a peri-urban settlement in the 
Klipfontein sub-district of Cape Town, with a combination of formal and informal houses. 
Out of a total population of   ~ 350 000, the unemployment rate is approximately 57%, and 
about 81% of the population lives in informal housing (Bekker et al, 2006).  
 
The Hannan Crusaid adolescent ARV clinic was launched in 2008, and primarily provides 
ART to ADLHIV from the Gugulethu area between the ages of 10 and 19 years, as per WHO 
definition. This service is provided in an adolescent friendly environment that takes into 
account adolescents’ challenging developmental needs in accordance ith the Youth Friendly 
Services initiative by Lovelife (Augustine, 2002).  Given that the PMTCT programme 
coverage in developing countries was only 45% in 2008, (Richter et al, 2010), the majority of 
the adolescents attending this  clinic also have a history of vertical transmission of HIV, and 
many of  them  were diagnosed and  had their treatment initiated at Red Cross children's 
hospital.  They are initially transferred into the main Hannan Crusaid ARV clinic, which has 
been providing adult and paediatric ART services to the Gugulethu community since 2002.  
They are then transferred into the above clinic soon after their 10
th
 birthday, and full 
disclosure is a pre-condition, prior to the transfer. Doctors, nurses and counselors dedicated to 





The following are some of the adherence barriers and facilitators highlighted by the study 
participants: 
Adherence barriers: many tended to forget when their routine was interrupted, e.g. during 
school holidays.  Other adherence barriers that the participants mentioned included: (i) 
Interference with social agenda, (ii) Inflexible dosing regimen (iii) ART side effects. What 
commonly emerged, despite the good intentions, were elements of guilt, resentment and at 
times rebelliousness, coupled with forgetfulness.   
“We were in the E/Cape.  I didn’t want to take the pills….I kept throwing them away.  
When my mom asked me if I took the pills, I’d say yes, when I did not take them but 
actually threw them away” (part 9:14yo M).   
With regard to adherence facilitator: Family support emerged as a major adherence enabler 















taking into their daily routine, (ii)  Use of e.g. cell-phone alarms, (iii) Using specific 
television programmes, commonly local ‘soap’s’ [soap operas] as reminders. When asked 
how they would ensure continued adherence when travelling, e.g. on an overnight school 
outing/camp, one participant said:   
“Kaloku I’ll take the pills with me, put them in the bag, and then go to the toilet to drink 




Most of the participants expressed hopefulness about the future, being on ART.  Many were 
intending to finish school.  Some expressed hopes of getting married and having families of 
their own.  However, there were some who expressed reservations, especially around having 
children.   Others expressed concerns around relationships.  Once again, disclosure, 
acceptance and support from partners were the specific concerns raised.  Quite a few 
concluded that they would rather have relations with a partner who is also living with HIV:  
“I think that HIV will affect my life… I wish I could find someone that will understand 
that I have HIV and that we can go through things together….I will get someone who 



























___ ___  
 
Date of Interview 
 
 
___ ___ /___ ___ /___ ___  
 
Interview Start Time 
 
 
Interview Stop Time 
 
 




Basic Demographic Information 
 
Identifier: Folder number 
I am going to ask you some questions about yourself and your experiences as an 
ADLHIV, some of the questions may be upsetting or may make you feel sad, if 
that happens, please tell the interviewer, and if you want to stop the interview 
for a while or completely, that will be ok.  If you feel sad and want to talk to 
someone about it afterwards, we will arrange for you to speak to one of our 
trained counsellors or the facility social worker. 
Before we start, are there any questions that you would like to ask the 
interviewer before we start? 


















Grade in school  
Name of school  
 Care-giver –parent  
Aunt/uncle   
Granny 
Other 
Level of education of care-giver  
Language spoken at home  
Live in a house or a shack  
How many people in the house/shack 
Hobbies/interests: What do you enjoy doing when you’re not at school? 
Who is your best friend? 
Age at ART initiation {get from patient notes} 
Duration on ART {get from patient notes} 
 
 
Section 1: Knowledge around HIV and attitude towards HIV: 
I would like to ask you questions about HIV: what you know about it. It does not 
matter if you don’t know the answers, and for some questions there are no right 
or wrong answers, we just want to find out what you think and feel. 
 
1.  How and where did you hear about HIV for the first time? 
 Probe:  At home 
  At school 
  At the clinic 
  In the street while playing/community 
(a) Who did you hear about it from? 
 Probe:  Parent/Care-giver 
    Peer/Friend 
    Relative 
    Health care worker (Dr/Counsellor) 
    Other 
(b) What was being said about it, when you first heard about it? 
 
2.  What do you know about HIV? 
 Probe:  Can draw a picture to describe 
(a) What do you think it looks like? 
 Probe:  Can draw a picture to describe 
(b) What do you think it does to the body? 
Probe:  Can draw a picture to describe 
(c) How do you think it affects your health, overall? 

















Section 2:  Questions around disclosure 
I would like to ask you questions concerning your HIV status and how you were 
first informed about your own status 
 
1.  How old were you when you found out that you are HIV+? 
2.  Who told you? 
(a) What did they say? 
 Probe:  Events surrounding disclosure 
  Did something happen to prompt it? 
  Who else was there? 
  Where you at home, in a private space or not? 
3.  Who have you spoken to about HIV/ART? 
 Probe:  Family, friends at school or the clinic, Dr, counsellor, other 
4.  .  Do you intend telling your friends or have you told any of your friends 
already? 
 Probe:  When? 
    If not, why not? 
(b) What are your fears if any, regarding disclosure to friends? 
(c) How do you think your friends might treat you when they find out your 
status? 
 
Section 3:  Questions around experience of HIV 
I would like you to share with me what it is like living with HIV 
 
1.  How did you feel when you were told that you are HIV+? 
 Probe:  Shocked, sad, confused, angry, nothing 
(a)  How do you feel now that you know? 
Probe:   relieved, sad, angry, confused  
(b) Did you have any suspicions about your status before you were told? 
 Probe: if so, what made you suspicious? 
(c) Did they explain to you how it happened? 
2. Since you were informed of your HIV status, have you had an 
opportunity to discuss the issue with anyone?    
Probe: with whom (care-giver, Dr, peers, counsellor) 
3.  Do you know other young people who are HIV+? 
  Probe:  who? 
  how did you find out? 
  how do you feel about those who are HIV+? 
4.  How did you feel when you realised that you are not the only one living 
with HIV? 
















Section 4. Questions around adherence 
Since you are on ART, I would like to ask you questions around your treatment 
and how you feel about taking medication all the time 
 
1.  Do you know the names of your medication? 
Probe: Who taught you? 
2.  It is very difficult to take your medication all of the time and many 
people struggle to do so. How much of the time do you take your 
medication? 
(a) Does anyone remind you to take your medication? 
(b) Aside from people, do you use other things to remind you to take your 
medication? 
c) Aside from forgetting, there are other reasons why people don’t always take 
their medication. What are those reasons for you? 
d) Is there anything you can think of that would make it easier for you to take 
your medication? 
 3.  Can you remember being sick? 
If yes, what was that like? What do you remember? 
4.  How do you feel about taking medication? 
(a)  Usually people take medication when they are sick and stop when they are 
well, but you have to take medication even when you are well: 
 Probe: Do you understand why? 
 Probe: How does that make you feel? 
5.  How long do you think you have to take the medication for and why? 
  (b) How do you feel about taking medication for the next 10 yrs? 
(c) How do you feel about taking medication all your life? 
6.  They say you have to take medication everyday: 
Probes: Do you ever forget to take your medication? 
What do you think makes you forget?  
 What do you do when you remember, later? 
 Who reminds you and how? 
When travelling (eg school outing, how do you deal with having to take 
medication)? 
How important do you think it is for you to continue to take your 
medication?  
 7.   Have you ever thought about stopping to take your medication? 
 Probes:  Why, and if not, why not 
(b)  Have you actually ever stopped taking your medication? 
 If the answer is yes then ask the following 
 Probes: Why did you stop? 
  How long did you stop taking your medication for? 
  How did you feel? 















8.  What effect do you think the medication has on your health? 
Probes: helping? if so how OR 
 causing harm? if so how, OR  
not making a difference, if so how so 
9.  What do you think the medication is doing to the virus 
 Probe: Can Draw a picture to describe 
10. What do you think are the good things about taking medication (all the 
time)? 
11.  (a) What do you think are the bad things about taking medication, if any? 
11. (b) What are the bad things about not taking medication? 
What do you think will happen? 
What are the good things about not taking medication? 
 
 
Section 5. Questions about the future 
Since you are on ART, I would like to ask you questions about how you see your 
future as a young person living with HIV. 
 
1.  Where do you see yourself in the next (e.g. 6/12, 1 yr., 5 yrs.) 
2.  If things were good, what would your life look like 
 Probes: in terms of your health, school, relationships with friends 
2(b) If things were bad what would your life look like 
Probes: in terms of your health, school, relationships with friends 
3.  What do you think you could do to achieve your life being good in (e.g. 
6/12, 1 yr., 5 yrs.) 
 Probes: in terms of adherence to medication, overall health, socially 
4.  What could others do to help you achieve this? 
 Probes: Care-givers, health-care givers, friends 
 
 
Those are all the questions I have got. Is there anything else you would like to 
tell me about what it is like to have HIV, or what it is like to take medication all 
the time?   
 
I would like to thank you for agreeing to participate in this study, and thank you 






















Focus group interview guides 
 




Grade in school 
Name of school  
Home language 
Residential Area 
Who do you live with 
 
Section 2: Community Attitudes 
I would like to ask you questions about what you’ve heard people in your 
communities say about HIV and how this has affected you. 
 
1.  When and where was the first time you heard about HIV? 
 Probes: Where: School, Home, Clinic, In the community 
      When: how long ago 
   how old were you? 
2.  What was said? 
 Were they saying good things? If so what? 
 Were they saying bad things? If so what? 
 Anything else? 
3.  Have you heard other children at school talking about HIV? 
 Probes: What were they saying? 
Were they talking about it in general or were they talking about 
someone else? 
Were they saying good things or bad things?  
4.  Have you heard other people in the community talking about HIV? 
 Probes: What were they saying? 
Were they talking about it in general or were they talking about 
someone else? 
Were they saying good things or bad things?  
5.  Have you heard other people in the clinic talking about HIV? 
 Probes: Was it a Patient, Dr, Counsellor, other 
 What were they saying? 
Were they talking about it in general or were they talking about someone 
else? 
Were they saying good things or bad things? 



















Section 3: Knowledge and attitudes among participants 
I would like to ask you questions about HIV: what you know about it. 
 
1.  Do you know people who are living with HIV? 
 Probes: Who? 
  Any relatives, neighbours? 
 
2.  What do you think of people who are living with HIV? 
 Probe: Good/Bad/different from everyone else 
 
3.  How do people contract HIV? 
 Probes: Who gets HIV/what kind of people?   
  Good/Bad/Anyone 
 
4.  How do you think people living with HIV are treated in the community?  
(b)  How do you think they should be treated? 
 
5.  How do you think adolescents living with HIV are treated in the 
community/ schools?  
(b)  How do you think they should be treated? 
 
6.  What is HIV? 
 Probe: Describe 
 
7.  What effect does HIV have on the body? 
 Probe: Good/Bad and what makes you think so 
 
8.  Since you found out that you are HIV+, how do you feel about being 
HIV+? 
 
9.  You know about HIV because you attend a youth friendly clinic and 
have been taught about HIV and what it does.  Do you think other 
adolescents know a lot as well?  
Probes: Why do you think so? What are they saying? How / where do you think 
they learn about HIV? 
If they are misinformed, how can they be better informed? 
 
10.  What do people say happens to those living with HIV? 
















Section 4:  Questions around disclosure 
I would like to ask you questions concerning your HIV status and how you were 
first informed about your own status 
 
 
1.  Have you spoken to anyone about HIV outside of the home? 
 Probes: Who, when, where and what did you say? 
(b)  How did they react? 
(c)  How do you feel now that you have told them?  
  Probe: has it made things better for you / worse for you?  
  If you haven’t spoken to anyone, why not? 
 
2.  What do you think will happen if your friends find out about your 
status? 
 Probe: How will that make you feel? 
  (b)  Do you think they would react differently if you heard it from you, or if 
they found out some other way? 
 
3.  If you were to tell someone, who would you tell? 
 Probes: Why that person? 
  When? 
 How? 
  What would you say? 
 
4. Have you ever brought a friend with you to the clinic?  
 Probes: If so, who? And why this particular person? 
  What did you tell them about the clinic? 
  Do they know your status? 
  What do you think they will do/say when they find out? 
(b) If not, would you consider bringing a friend with you to the clinic? 
Section 5:  Questions around adherence to ART 
Since you are on ART, I would like to ask you questions around your treatment 
and how you feel about taking medication all the time 
 
1.  What have you been told about how long you need to take medication 
for? 
 Probes: How do you feel about that? 
  Do you think you can, even when you are not sick? 
  Why do you think you need to take medication all the time? 
  What does it mean to be adherent (what does it mean to you)? 
What do you think will happen if you don’t take your medication?  
 















 Probes: If so why/ if not why not? 
What effect do you think the medication has on your health/ on your 
body? 
 
3.  It is very difficult to take your medication all the time and many people 
have problems in doing so. What problems have you had with adherence to 
your ART regimen? 
 Probes: What makes it difficult? 
  What makes it easy? 
  What do you use as a reminder? 
What else would help you to take your medication? 
 
4.  What, if anything, do you think will happen if you don’t take your 
medication? 
 
5.  Do you think there are other things that will help or cause harm other 
than ART? 
 
6.  What advise or suggestions would you give to others who may be 
experiencing any problems with?  
being an ADLHIV or  
adhering to their treatment regimen?  
7.  What advise or suggestions would you give to others about what they 
can expect with? 
 being an ADLHIV?  
with adhering to their treatment regimen?  
Section 6:  The future: Note gender differences 
1.  How do you see your future living with HIV? 
 
2.  How do you see your future being on ART for life? 
 
 Probes: Finishing school 
  Remaining healthy 
  Jobs 
For 13-15yr olds: Dating 
   Getting married 
   Having children 
   Disclosure to partner 

















Those are all the questions I have got. Is there anything else any of you would 
like to tell me about what it is like to have HIV, or what it is like to take 
medication all the time?   
 
I would like to thank you all for agreeing to participate in this study, and thank 






















FORM A: Parental Consent 
 
 
University of Cape Town 
CONSENT TO PARTICIPATE IN RESEARCH 
 
Study title: Seeing HIV through the eyes of perinatally infected adolescents 
living with HIV, on antiretroviral treatment. 
 
 
Dr Pearl Holele from the school of Public Health and Family Medicine is conducting a study 
on the above topic. This will include examining how young, asymptomatic adolescents living 
with HIV experience HIV, and how these experiences ultimately impact on their adherence to 
anti-retroviral treatment.  This research study is conducted for post-graduate degree purposes. 
 
The participation of your adolescent in either the one-on-one interviews or focus group 
discussions that will be conducted for this study will be highly appreciated. 
The Isi-Xhosa version of this form is will be read out to you as the parent/legal guardian of 
the participating adolescent.  If you give your permission for your adolescent to take part in 
this research study, you will then be asked to sign it prior to the interview. Before you sign 
the consent form, we will ask you a few questions to ensure that you understand the 
information given on the consent form.  You will be given a copy of the consent form, and 
the other copy will be kept with the interview material for our records.  
 
Purpose of the study 
To talk to adolescents between the ages of 10 and 15yrs, who have been living with HIV 
since birth, to find out how they experience HIV.  In other words, what their understanding of 
their illness is, their feelings and attitudes around living with HIV, and how they think HIV 
affects their bodies and self-image.  Also, what their understanding is of the need to take 

















Your adolescent’s part in the study  
If you give your permission for your adolescent to take part in this research study, a trained 
fieldworker will ask your adolescent to respond to a series of questions around what they 
know and understand about HIV and the need for lifelong antiretroviral treatment.  They will 
also be asked questions around stigma, disclosure issues and how they see the future as 
individuals living with HIV. The fieldworker will either speak to them individually (i.e. a 
one-on-one interview) or as part of a group of 6 adolescents (i.e. a focus group discussion).  
Each interview or focus group discussion will last for about an hour. The interview or focus 
group discussion will be captured on an audio-recorder with your permission.   In addition, a 
youth counselor known to you and your adolescent will be present to facilitate the process. 
 
Potential risks for the adolescent 
HIV in itself is a fairly sensitive subject and the adolescents who are asked to take part in the 
study are still fairly young.   The adolescents may therefore find speaking about HIV and 
how it affects their lives upsetting, because it may remind them of painful experiences that 
they’ve had.  Your adolescent will be informed that they do not have to answer any particular 
question or discuss any subject or issue that they are not comfortable discussing.  After the 
interview, your adolescent will be referred to a trained youth counselor or social worker for 
debriefing if the need arises. 
Participation and withdrawal 
Your adolescent does not have to take part in the study, even if you as the parent/legal 
guardian have given your consent for them to do so.  In addition, even though you have 
signed and consented to have your adolescent take part in the study, you have a right to 
withdraw your adolescent’s participation in the study at any time.  Also, your adolescent has 
the right to discontinue their participation in the study at any time during this process.   If you 
choose not to allow your adolescent to take part in the study or if you withdraw their 
participation in the study once you have agreed to have them participate, it will not affect the 
care that they receive at the clinic or how the people who work at the clinic treat them or you.  
Potential benefits of the research 
Your adolescent will not benefit directly from taking part in this study; however, by doing 















who are living with HIV and are on antiretroviral treatment.  It is hoped that the study 
findings will be used to influence policy on the management of adolescent health, to make the 
services more adolescent friendly.  
 
Confidentiality and Anonymity 
 
If you give your consent for your adolescent to take part in this study, be assured of the 
following: 
(a)  They will be given a code number 
(b)  Their name and all other personal information will be stored under that code number, to 
ensure anonymity 
(c)  All their views, feelings, opinions, etc. will be used for research purposes only, and will 
only be disclosed with their permission  
(d)  The information obtained from your adolescent will only be available to the researcher 
and fieldworker, and will be kept in a safe place at all times. 
 
Confidentiality in Focus Groups (only applicable to those participating in focus group 
discussions) 
If you give your consent for your adolescent to take part in a focus group discussion, they 
will form part of a group of 6 adolescents in total.  In addition to the above measures, we will 
also ask the 6 focus group members not to discuss information shared during the focus group 
discussion with people that were not part of the focus group.  However, please be aware that 
in this instance, confidentiality cannot be guaranteed and is dependent on each focus group 
members adhering to this agreement. 
 
Researcher medico-legal obligations 
Researchers working with children have certain legal obligations.   This is to ensure that 
those children that are found to be in need of care or are in danger, are reported to the 
appropriate authorities, so that those children can get the necessary help. Thus, because of 
these obligations, the things that your adolescent tells us during the interview regarding their 
behaviour will be private unless it turns out that they are in a situation where they are being 
hurt or taken advantage of by someone; or conversely, if they are in danger of harming 
themselves or another person.   















 (a)  If it turns out that they are being abused or neglected 
 (b)  If it turns out that they have been the victim of a sexual offense, e.g. rape 
 (c)  If it turns out that they are in danger of harming themselves or others 
 (d)  If it turns out that they are not attending school and they are under the age of 15. 
If any of the above is unearthed during the interviews, not only will the adolescent be 
informed of the necessary steps to be taken, but they will also be provided with the necessary 
and appropriate support.  In addition, we will assist in informing you as parent/legal guardian, 
so that they can get you the support that they need to deal with the situation. 
 
Payment for taking part 
All study participants and their parents/legal guardians will be offered taxi-fare for their trip 
to and from the clinic and also some refreshments during the interview sessions.   
 
Identification of investigator 






Rights of research subjects 
If you have questions or concerns about your rights or the rights of your adolescent while 
they are taking part in the study, there is a team of researchers and doctors who are there to 
make sure that the research is done in a way that is safe and proper for those who have been 
asked to take part in the study. They can be contacted at: The Research Office, Faculty of 






















Questions to ensure clarity 
If you give your permission for your adolescent to take part in this research study, we would 
like to ask you a few questions to ensure that you understood the information given on the 
consent form, before you sign it: 
(a)  Is there anything more that you would like to know? 
(b)  Could you explain to me what we are going to do and what your adolescent would need 
to do if they agree to participate in the study  
(c)  What worries you most if you were to choose to have your adolescent participate in the 
study? 
(d)  How long will the interview or focus group discussion last? 






I                                                               (name of parent/legal guardian) declare that I have 
read and understood the above information and I was given adequate time to consider my 
child’s participation in the study and my questions were answered satisfactorily. I hereby 
consent to the participation of my child in this study. 
                             (Signature)                 Date.  
Relationship to the adolescent: ______________________                
       
 
 
Field worker  
I declare that I read this document to the participant’s mother, in Isi-Xhosa.  I have tried to 
answer her questions to the best of my knowledge.  
Date:                                   Signature of Fieldworker:_____________________               
















FORM B: Adolescent Assent 
 
 
University of Cape Town 
CONSENT TO PARTICIPATE IN RESEARCH 
 
Study title: Seeing HIV through the eyes of perinatally infected adolescents 




Dr Pearl Holele from the school of Public Health and Family Medicine is conducting a study 
on the above topic. This will include examining how young, asymptomatic adolescents living 
with HIV experience HIV, and how these experiences ultimately impact on their adherence to 
anti-retroviral treatment.  This research study is conducted for post-graduate degree purposes. 
 
We would like to invite you, with your parent/legal guardian’s permission, to participate in 
the one-on-one interviews or focus group discussions which will be conducted for the above 
study. You are allowed to take some time to decide whether or not you would like to be 
included, or to speak to someone you trust such as your parent or counsellor to help you in 
your decision. 
In order to obtain your assent, the content of the assent form will be read and explained to 
you in Isi-Xhosa, to ensure that you understand what the process entails and what is expected 
of you. If you choose not to give your assent, you will not to be included in the study, even if 
your parent/legal guardian has consented to your participation.  Before you sign the assent 
form, we will ask you a few questions to ensure that you understand the information given on 
the assent form.  A copy of the assent is to be kept by your consenting parent/legal guardian, 
and the other copy is to be kept with the interview material for our records.  
 
 
What is the study about 
We would like to talk to adolescents between the ages of 10 and 15yrs, who have been living 
with HIV since birth, like you.  Our aim is to find out how you and your peers experience 















around living with HIV, and how you think HIV affects your bodies and self-image.  Also, 
what your understanding is of the need to take lifelong antiretroviral treatment. 
 
What is expected of me  
If you agree to take part in this research study, a trained fieldworker will ask you some 
questions.  She will either speak to you alone, in the form of an interview, or in the form of a 
group discussion, with 5 other adolescents.  The questions will be about how much you know 
and understand about HIV; Taking antiretroviral treatment; Stigma, disclosure issues and 
how you see the future as an adolescent living with HIV. The interview will last for about an 
hour, it will be captured on an audio-recorder with your permission, and a youth counselor 
that you are familiar with will be present to facilitate the process. 
 
What are the potential risks 
HIV in itself is a fairly sensitive subject and because you are still fairly young, you may 
therefore find speaking about HIV and how it affects your life upsetting, because it may 
remind you of painful experiences that you’ve had.  Please be assured that you do not have to 
answer any particular question or discuss any subject or issue that you are not comfortable 
discussing.  After the interview, you will be referred to a trained youth counselor or social 
worker for debriefing if the need arises. 
Participation and withdrawal 
You do not have to agree to take part in the study, even if your parent/legal guardian has 
given their permission for you to do so.  Also, even though you have agreed take part in the 
study, you have the right to withdraw from participating in the study at any time during this 
process.  If you choose not to take part in the study or if you withdraw once you have agreed 
to participate, it will not affect the care that you receive at the clinic or how the people who 
work at the clinic treat you.  
 
Potential benefits of the research 
You will not benefit directly from taking part in this study.  However, we hope that the study 
will give us a better understanding of what it is like living with HIV and taking antiretroviral 















will be used to come up with health programmes that will deal with the concerns and 
challenges highlighted in the study findings, which will result in services that are more 
adolescent friendly.   
Confidentiality and Anonymity 
 
If you agree to take part in this study, be assured of the following: 
(a)  You will be given a code number 
(b)  Your name and all other personal information will be stored under that code number, to 
ensure anonymity 
(c)  All your views, feelings, opinions, etc. will be used for research purposes only, and will 
only be disclosed with your permission  
(d)  The information obtained from you will only be available to the researcher and 
fieldworker, and will be kept in a safe place at all times. 
 
Confidentiality in Focus Groups (only applicable to those participating in focus group 
discussions) 
 
If you agree to participate in a focus group discussion then 6 of you will gather together and 
answer questions, sharing your ideas, feelings and opinions about living with HIV and taking 
antiretroviral treatment.  In order to ensure privacy, we will also ask each of you in the group 
to commit to not discuss information shared during the focus group discussion with people 
that were not part of the focus group.  However, please be aware that in this instance 
confidentiality cannot be guaranteed and is dependent on each member of the focus group 
adhering to this agreement. 
 
Researcher medico-legal obligations 
Researchers working with children have certain legal obligations.   This is to ensure that 
those children that are found to be in need of care or are in danger, are reported to the 
appropriate authorities, so that those children can get the necessary help. Thus, because of 
these obligations, the things that you tell us during the interview regarding your behaviour 
will be private unless it turns out that you are in a situation where you are being hurt or taken 
advantage of by someone; or conversely, if you are in danger of harming yourself or another 
person.   
For instance we Will be obliged to inform authorities, but not your parents: 















 (b)  If it turns out that you have been the victim of a sexual offense, e.g. rape 
 (c)  If it turns out that you are in danger of harming yourself or others 
 (d)  If it turns out that you are not attending school and you are under the age of 15. 
If any of the above is unearthed during the interviews, not only will you be informed of the 
necessary steps to be taken, but you will also be provided with the necessary and appropriate 
support.  In addition, we will assist in informing your parent/legal guardian, so that they can 
give you the support you need to deal with the situation. 
 
Payment for participation 
All study participants and their parents/legal guardians will be offered taxi-fare for their trip 
to and from the clinic and also some refreshments during the interview sessions.   
 
Identification of investigator 






Rights of research subjects 
If you have questions or concerns about your rights there is a team of researchers and doctors  
who are there to make sure that the research is done in a way that is safe and proper for those 
who have been asked to take part in the study. They can be contacted at: The Research 
Office, Faculty of Health Sciences at the University of Cape Town on 021 650 4015.  
 
Questions to ensure clarity 
If you agree to take part in this research study, we would like to ask you a few questions to 
make sure that you understood the information given on the assent form, before you sign it: 
(a)  Is there anything more that you would like to know? 
(b)  Could you explain to me what we are going to do and what you would need to do if you 
agree to participate in the study  
(c)  What worries you most if you were to choose to participate in the study? 
(d)  How long will the interview or focus group discussion last? 


















I                   (name of parent/legal guardian) declare that I have read and understood the 
above information and I was given adequate time to consider my child’s participation in the 
study and my questions were answered satisfactorily. I hereby consent to the participation of 
my child in this study. 
                             (Signature)                 Date.                 





I                    (name of adolescent) declare that the information about this study has been 
explained to me, and I understand what the study is about and my role once I agree to take 





FIELD WORKER  
I declare that I read and explained this document to the participant, in Isi-Xhosa.  I have tried 
to answer their questions to the best of my knowledge.  
Date:      Signature Fieldworker: 
Contact details fieldworker: 
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include a 200-word summary abstract. A combined total of 1 figure, table or illustration and 
10 references will be accepted. 
 
Editorial Correspondence: Letters regarding articles published in the Journal within the 
proceeding 6 months are strongly preferred. Letters should not exceed 400 words. This 
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editors. Commentaries serve as a forum for changes in adolescent healthcare training, 
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